Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- COMBI.ST
- Price
- 2.38
- Stock movement up
- +- (%)
- Company name
- Combigene AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 47.13M
- Ent value
- -24.11M
- Price/Sales
- 51.11
- Price/Book
- 0.55
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -28.25%
- 1 year return
- -40.35%
- 3 year return
- -37.73%
- 5 year return
- -25.24%
- 10 year return
- -
Last updated: 2025-04-15
DIVIDENDS
COMBI.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 51.11 |
| Price to Book | 0.55 |
| EV to Sales | -26.15 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 19.80M |
| EPS (TTM) | -1.87 |
| FCF per share (TTM) | -1.55 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 922.00K |
| Gross profit (TTM) | -24.82M |
| Operating income (TTM) | -32.11M |
| Net income (TTM) | -37.08M |
| EPS (TTM) | -1.87 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -2692.19% |
| Operating margin (TTM) | -3482.97% |
| Profit margin (TTM) | -4021.69% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 76.69M |
| Net receivables | 0.00 |
| Total current assets | 77.82M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 91.18M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 5.45M |
| Total liabilities | 5.45M |
| Shareholder's equity | 85.74M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -30.72M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -30.72M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -43.25% |
| Return on Assets | -40.66% |
| Return on Invested Capital | -43.25% |
| Cash Return on Invested Capital | -35.83% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.64 |
| Daily high | 2.64 |
| Daily low | 2.38 |
| Daily Volume | 12K |
| All-time high | 160.00 |
| 1y analyst estimate | 2.10 |
| Beta | 1.53 |
| EPS (TTM) | -1.87 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 23 May 2025 |
Downside potential
Loading...
Downside potential data
| COMBI.ST | S&P500 | |
| Current price drop from All-time high | -98.51% | -12.04% |
| Highest price drop | -99.08% | -56.47% |
| Date of highest drop | 31 Oct 2024 | 9 Mar 2009 |
| Avg drop from high | -82.77% | -11.07% |
| Avg time to new high | 131 days | 12 days |
| Max time to new high | 1362 days | 1805 days |
COMPANY DETAILS
Marketcap
47.13M
Marketcap category
Small-cap
Description
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden.
Employees
10
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The European market has experienced a significant downturn, with the pan-European STOXX Europe 600 Index suffering its largest drop in five years due to heightened U.S. trade tariffs. Despite these ch...
April 10, 2025